LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, announced it has filed a registration statement on Form F-1 (the Registration Statement) with the U.S. Securities and Exchange Commission (the SEC) relating to a proposed initial public offering (IPO) in the United States of its American Depositary Shares (ADSs), each representing one ordinary share.

All ADSs to be sold in the proposed IPO will be offered by Freeline. Freeline has applied to list its ADSs on The Nasdaq Global Select Market under the ticker symbol FRLN. The number of ADSs to be offered and the pricing terms for the proposed IPO have not yet been determined. The offering is subject to market conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering.

The Registration Statement relating to the ADSs has been filed with the SEC but has not yet become effective. The ADSs may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective.

The Registration Statement can be accessed through the SECs EDGAR database and contains further information relating to Freeline.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The securities referred to in this announcement are to be offered only by means of a prospectus. When available, copies of the preliminary prospectus can be obtained from any of the joint book-running managers for the offering, J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Evercore Group L.L.C. at Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

Further informationJW CommunicationsJulia Wilson+44 (0) 7818 430877juliawilsonuk@gmail.com

About FreelineFreeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the UK and has operations in Germany and the US.

View original post here:

Freeline files registration statement for proposed initial public offering in the United States - GlobeNewswire